Increase in human basophils IgE-mediated stimulation by omalizumab: a role for membrane FcγRs?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. The role of basophils as innate immune regulatory cells in allergy and immunotherapy.Human vaccines & immunotherapeutics · 2018
   Review
2. Road map for the clinical application of the basophil activation test in food allergy.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2017
   Review
3. Immunotherapy in allergy and cellular tests: state of art.Human vaccines & immunotherapeutics · 2014
   Review

Corrections and comments

• Commented on by
  Reply: To PMID 23791510.2014
• Comment on
  Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation.2013

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as